Rare disease gene therapy trials are growing, but most still stop at the first clinical steps
Rare diseases now occupy a substantial share of the gene therapy pipeline, yet the field is still weighted toward exploratory work rather than confirmatory development. A registry-based cross-sectional analysis identified 1,464 registered gene therapy studies, and 646 of them — 44.13% — addressed 175 distinct rare diseases. The pace of development has clearly accelerated: annual initiation of rare-disease studies rose from 21 in 2015 to 73 in 2024.
The signal is encouraging, but it is not evenly distributed.
The portfolio is concentrated in a small set of indications that have long been biologically attractive for gene transfer because a single molecular correction can plausibly alter the course of disease. Hemophilia A and B, retinitis pigmentosa, Duchenne muscular dystrophy, and sickle cell disease appeared most often in the registry. Those disorders share a practical advantage for development: their pathobiology is well defined, the causal gene defect is usually known, and measurable clinical or biomarker endpoints can be tracked over time. In a field where target validation and delivery remain major barriers, that combination gives sponsors and investigators a workable starting point.
Early-phase design still dominates the rare-disease pipeline
Among the 646 rare-disease studies, 547 were interventional, representing 84.67% of the cohort. Even so, most trials remained at the earliest stages of human testing. A total of 408 studies, or 63.16%, were classified as early phase I, phase I, or phase I/II. Only a minority had moved far enough along the development pathway to suggest broader readiness for efficacy confirmation or comparative assessment.
This matters because gene therapy development is not only about demonstrating biological activity; it is about proving durability, manufacturing consistency, and acceptable safety in conditions that often have limited natural history data. For rare diseases, the move from proof-of-concept to later-phase evidence is unusually difficult. Small patient pools, heterogeneous phenotypes, and uneven global access can keep programs clustered in early development for years. In practical terms, many of these studies are still asking the same foundational question: can the vector, editing platform, or transgene achieve enough target engagement to justify larger trials?
The pediatric dimension is equally important. Of the registered rare-disease studies, 402 — 62.23% — permitted pediatric enrollment. That is unsurprising, because many severe rare disorders present in childhood and cause irreversible injury early in life. In neuromuscular disease, inherited retinal disease, and pediatric hematologic conditions, the therapeutic window may narrow quickly as organ damage accumulates. Gene therapy is often most biologically plausible before end-stage structural damage sets in, when the relevant tissue remains salvageable and the disease burden has not yet become fixed.
U.S. sites dominate the global trial map
Geography remains tightly concentrated. The United States was listed as a study location in 410 trials, or 63.47% of the rare-disease cohort. That concentration likely reflects the interaction of regulatory infrastructure, sponsor density, and patient recruitment networks that can support highly specialized cellular and gene-based studies. It also suggests that access to experimental gene therapy remains uneven across regions, especially for disorders that require longitudinal follow-up, specialized manufacturing, and highly coordinated safety monitoring.
Cross-border participation is not a trivial detail in rare disease. Many conditions are so uncommon that single-country recruitment can slow enrollment to a crawl, especially once first-line eligible patients have already been approached by other studies or by commercially available products. The geographic skew in this registry implies that the field may be missing opportunities to build broader natural history comparisons and more generalizable trial populations. For diseases with variable penetrance, genotype–phenotype overlap, or distinct ancestry-related mutation patterns, a narrower geographic footprint can limit what later-phase results can safely mean.
FDA approvals already cover many rare-disease indications
The regulatory side of the story is more mature than the trial pipeline alone might suggest. Of 30 approved gene therapy products identified in the analysis, 24 — 80.00% — had at least one rare-disease indication. Collectively, those products covered 16 indications. This is a meaningful reminder that rare diseases are not a niche afterthought within gene therapy; they are one of its central clinical use cases.
Regulatory approval in this setting does not erase development challenges. It does, however, show that gene therapy has crossed from conceptual medicine into routine regulatory science for selected disorders. Hemophilia, inherited retinal disease, spinal muscular atrophy, and selected hematologic conditions have already demonstrated that a one-time or limited-course genetic intervention can reach approval when the biology is clear and the clinical endpoint is compelling enough to support risk-benefit decisions. Even so, approval counts should not be mistaken for broad maturity across the field. Most rare diseases still have no approved disease-modifying option, and many remain in the earliest pre-commercial stages.
The field’s bottleneck is no longer proof of concept alone
The registry data point to a development pipeline that is expanding in volume but still uneven in depth. Rare diseases accounted for nearly half of all registered gene therapy studies in the dataset, yet the overwhelming share of those studies remained early phase. The central limitation is not a lack of scientific ambition. It is the difficulty of moving from mechanistic plausibility to durable, reproducible evidence in tiny populations spread across disparate health systems.
For clinicians, the pattern has direct implications. Families facing a rare inherited disorder may see an expanding menu of trials, but many will still be enrolled in studies designed to answer feasibility questions rather than confirm clinical benefit. For investigators, the priority is obvious: later-phase evaluation, better international coordination, and trial designs that can handle low prevalence without sacrificing interpretability. The dominance of early-phase work suggests the field is still building the evidence base needed to determine which genetic interventions truly change the trajectory of rare disease, and which only appear promising at the first pass.
The published dataset ends at an October 2025 cutoff, so the picture will continue to shift as new studies start, mature, or close. What this registry captures is a field in motion, with clear regulatory footholds but still limited late-stage depth across most rare indications.